Abstract
Cancer cells dramatically alter their metabolism in order to increase the production rate of intermediates required for nucleic and fatty acid biosynthesis in rapidly proliferating cells. While not well understood, dysregulation of oncogenes and tumour suppressors appears to result in the altered expression of specific isoforms of glycolysis proteins. A full understanding of glycolytic alterations in cancer through a systems biology approach requires tools to observe changes in the set of proteins that make up the glycolytic proteome. We propose that a targeted proteomics approach employing multiple reaction monitoring (MRM) is an excellent strategy to quantitatively monitor sets of proteins, such as those making up the glycolytic proteome. MRM is particularly well suited to proteins of glycolysis as they are of moderate to high abundance. Such systems-based efforts provide a means to understand the mechanisms for an altered glycolytic proteome in cancer, perhaps leading to novel drug targets and metabolic signatures for use in cancer prognosis.
Keywords: Cancer, glycolysis, MRM, targeted proteomics, warburg effect, metabolism, nucleic, fatty acid biosynthesis, dysregulation, renal cell carcinomas, Pyruvate Kinase M2, Hexokinase 2 (HK2)
Current Proteomics
Title: Monitoring the Switch: The Warburg Effect and Targeted Proteomic Analysis of Cancer Metabolism
Volume: 9 Issue: 1
Author(s): J. Patrick Murphy, Patrice D. Cote and Devanand M. Pinto
Affiliation:
Keywords: Cancer, glycolysis, MRM, targeted proteomics, warburg effect, metabolism, nucleic, fatty acid biosynthesis, dysregulation, renal cell carcinomas, Pyruvate Kinase M2, Hexokinase 2 (HK2)
Abstract: Cancer cells dramatically alter their metabolism in order to increase the production rate of intermediates required for nucleic and fatty acid biosynthesis in rapidly proliferating cells. While not well understood, dysregulation of oncogenes and tumour suppressors appears to result in the altered expression of specific isoforms of glycolysis proteins. A full understanding of glycolytic alterations in cancer through a systems biology approach requires tools to observe changes in the set of proteins that make up the glycolytic proteome. We propose that a targeted proteomics approach employing multiple reaction monitoring (MRM) is an excellent strategy to quantitatively monitor sets of proteins, such as those making up the glycolytic proteome. MRM is particularly well suited to proteins of glycolysis as they are of moderate to high abundance. Such systems-based efforts provide a means to understand the mechanisms for an altered glycolytic proteome in cancer, perhaps leading to novel drug targets and metabolic signatures for use in cancer prognosis.
Export Options
About this article
Cite this article as:
Patrick Murphy J., D. Cote Patrice and M. Pinto Devanand, Monitoring the Switch: The Warburg Effect and Targeted Proteomic Analysis of Cancer Metabolism, Current Proteomics 2012; 9 (1) . https://dx.doi.org/10.2174/157016412799746263
DOI https://dx.doi.org/10.2174/157016412799746263 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Mass spectrometry data acquisition and analysis for proteomics
The Thematic Issue on "Mass spectrometry data acquisition and analysis for proteomics" aims to explore the latest advancements and challenges in the field of proteomics through the lens of mass spectrometry. Proteomics, the large-scale study of proteins and their functions, plays a crucial role in understanding various biological processes and ...read more
Peptides: State-of-Art and Commercialisation Hurdles
The Editors of the Current Proteomics (CP) journal are highly privileged to welcome scientists to submit their scientific research and review articles to be considered for publication in the upcoming thematic issue. The topics should cover various aspects of peptides in regard to their synthetic methodologies, formulation approaches, pharmacological challenges, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews The Role of Flavonoids in Inhibiting IL-6 and Inflammatory Arthritis
Current Topics in Medicinal Chemistry Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry MicroRNAs: A Novel Non-Invasive Biomarker for Patients with Urological Malignancies
Current Pharmaceutical Biotechnology Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Current Drug Targets Old Drugs-Current Perspectives
Current Pharmacogenomics Chemical & RNAi Screening at MSKCC: A Collaborative Platform to Discover & Repurpose Drugs to Fight Disease
Combinatorial Chemistry & High Throughput Screening Targeted-Therapy in Advanced Renal Cell Carcinoma
Current Medicinal Chemistry Repeated Restraint and Nerve Growth Factor Administration in Male and Female Mice: Effect on Sympathetic and Cardiovascular Mediators of the Stress Response
Current Neurovascular Research The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry HE4 is a Beneficial Biomarker in Endometrial Adenocarcinoma
Current Women`s Health Reviews Simultaneous Optimization of Cisplatin-Loaded PLGA-mPEG Nanoparticles with Regard to their Size and Drug Encapsulation
Current Nanoscience Recurrent Hepatitis C After Liver Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections:
Recent Patents on Biomarkers The Methylerythritol Phosphate Pathway and its Significance as a Novel Drug Target
Current Pharmaceutical Biotechnology The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Involvement of CD24 in Multiple Cancer Related Pathways Makes It an Interesting New Target for Cancer Therapy
Current Cancer Drug Targets Proteasome Regulators: Activators and Inhibitors
Current Medicinal Chemistry Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Cytokines and their Antagonists as Therapeutic Agents
Current Medicinal Chemistry